Binding properties of dipropyltryptamine at the human 5-HT1a receptor

Pharmacology

Volumn 74, Issue 4, 2005, Pages 193-199

  Thiagaraj, Harish V ^a   Russo, Ethan B ^a   Burnett, Andrea ^a   Goldstein, Eric ^a   Thompson, Charles M ^a   Parker, Keith K ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

S GTP; cAMP; Hallucinogens; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CYCLIC AMP; DIPROPYLTRYPTAMINE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); SEROTONIN 1A RECEPTOR; TRITIUM; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; IC 50; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL MODEL;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; KINETICS; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SULFUR RADIOISOTOPES; TRANSFECTION; TRITIUM; TRYPTAMINES;

EID: 22544467466     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085649     Document Type: Article

References (44)

1. Ott J: Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History, ed 2. Kennewick/WA, Natural Products Co, 1996.
2. Shulgin AT: Psychotomimetic agents related to the catecholamines. J Psychedelic Drugs 1969;2:14-19.
3. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA: International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
4. Barnes NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152.
5. Soskin RA: Dipropyltryptamine in psychotherapy; in Masserman JH (ed): Current Psychiatric Therapies. New York, Grune & Stratton, 1975, vol 15, pp 147-156.
6. Haines T, et al: Living with our drug policy. Fordham Urban Law J 2000;28:92-129.
7. Barker SA, Monti JA, Christian ST: N,N-dimethyltryptamine: An endogenous hallucinogen. Int Rev Neurobiol 1981;22:83-110.
8. Pierce PA, Peroutka SJ: Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 1989;97:118-122.
9. McKenna DJ, Repke DB, Lo L, Peroutka SJ: Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 1990;29:193-198.
10. Glennon RA, Teitler M, Sanders-Bush E: Hallucinogens and serotonergic mechanisms. NIDA Res Monogr 1992;119:131-135.
11. Deliganis AV, Pierce PA, Peroutka SJ: Differential interactions of dimethyltryptamine with 5-HT1 a and 5-HT2a receptors. Biochem Pharmacol 1991;41:1739-1744.
12. Hollister LE: Chemical Psychoses: LSD and Related Drugs. Springfield. Thomas, 1968.
13. Siever LJ, Kahn RS, Lawlor BA, Trestman RL, Lawrence TL, Coccaro EF: Critical issues in definingthe role of serotonin in psychiatric disorders. Pharmacol Rev 1991;43:509-525.
14. Russo EB: Headache treatments by native peoples of the Ecuadorian Amazon: A preliminary cross-disciplinary assessment. J Ethnopharmacol 1992;36:193-206.
15. Russo EB: Schedule 1 research protocol: An investigation of psychedelic plants and compounds for activity in serotonin receptor assays for headache. Bull Multidiscipl Assoc Psychedelic Stud 1997;7:4-8.
16. Peroutka SJ: Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829-839.
17. Peroutka SJ, Havlik S, Oksenberg D: Anti-migraine drug interactions with cloned human 5-hydroxytryptamine-1 receptor subtypes. Headache 1993;33:347-350.
18. Ferrari MD, Saxena PR: 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995;2:5-21.
19. Shulgin A, Shulgin A: TiHKAL: The Continuation. Berkeley/CA, Transform Press, 1997.
20. Repke DB, Grotjahn DB, Shulgin AT: Psychotomimetic N-methyl-N- isopropyltryptamines: Effects of variation of aromatic oxygen substituents. J Med Chem 1985;28:892-896.
21. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts J, Barker EL, Nichols DE: Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 2000;43:4701-4710.
22. Drug Enforcement Administration (DEA), Department of Justice, 2003: Schedules of controlled substances: Temporary placement of α- methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I. Final rule. Federal Register April 4; 2003;68:16427-16430.
23. Arthur JM, Casanas SJ, Raymond JR: Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1a receptors. Biochem Pharmacol 1993;45:2337-2341.
24. Hayataka K, O'Connor MF, Kinzler N, Weber JT, Parker KK: A bioactive peptide from the transmembrane 5-intracellular loop 3 region of the human 5-HT1a receptor. Biochem Cell Biol 1998;76:657-660.
25. Ortiz TC, Devereaux MC, Parker KK: Structural variants of a human 5-HT1a receptor intracellular loop 3 peptide. Pharmacology 2000;60:195-202.
26. Cowen PJ: Psychopharmacology of 5-HT1a receptors. Nucl Med Biol 2000;27:437-439.
27. Julius D, Huang KN, Livelli TJ, Axel R, Jessel TM: The 5-HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc Natl Acad Sci USA 1990;87:928-932.
28. Lanfumey L, Hamon M: Central 5-HT1a receptors: Regional distribution and functional characteristics. Nucl Med Biology 2000;27:429-435.
29. Meng EC, Bourne HR: Receptor activation: What does the rhodopsin structure tell us? Trends Pharmacol Sci 2001;22:587-593.
30. Bikker JA, Trumpp-Kallmeyer S, Humblet C: G-protein-coupled receptors: Models, mutagenesis, and drug design. J Med Chem 1998;41:2911-2927.
31. Sakmar TP, Menon ST, Marin EP, Awad ES: Rhodopsin: Insights from recent structural studies. Annu Rev Biophys Biomol Struct 2002;31:443-484.
32. Fenrick R, Pou C, Beliveau M, Fargin A: The human 5-hydroxytryptamine 1a receptor differentially modulates phospholipase C and adenylyl cyclase activities. Gen Pharmacol 1996;27:263-268.
33. Thiagaraj HV, Ortiz TC, Burnett A, Parker KK: G protein coupling and activation characteristics of intracellular loops 2 and 3 of the 5-HT1a receptor. Trends Comp Biochem Physiol 2002;9:117-129.
34. Rasmussen K, Rocco VP: Recent progress in serotonin (5-HT)1a receptor modulators. Annu Rep Med Chem 1995;30:1-9.
35. Robichaud AJ, Largent BL: Recent advances in selective serotonin receptor modulation. Annu Rep Med Chem 2000;35:11-20.
36. Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN: The recombinant 5-HT1a receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999;127:1751-1764.
37. Thiagaraj HV, Russo EB, Thompson CM, Parker KK: Pharmacology of dipropyltryptamine at human 5-HT1a receptors. Soc Neurosci Abstr 2001;31:266.7.
38. Kobilka BK, Frielle T, Collins S, Yang-Feng T, Kobilka TS, Francke U, Lefkowitz RJ, Caron MG: An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 1987;329:75-79.
39. Fargin A, Raymond JR, Lohse MJ, Kobilka BK, Caron MG, Lefkowitz RJ: The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1a receptor. Nature 1988;335:358-360.
40. 3H]spiroxatrine labels a serotonin-1a-like site in the rat hippocampus. Life Sci 1987;41:1567-1576.
41. Bradford MM: A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
42. Weber JT, O'Connor MF, Hayataka K, Colson N, Medora R, Russo EB, Parker KK: Activity of parthenolide at 5-HT2a receptors. J Nat Prod 1997;60:651-653.
43. Wieland T, Jacobs KH: Measurement of receptor-stimulated guanosine 5′-O-(γ-thio) triphosphate) binding by G proteins. Meth Enzymol 1994;237:3-27.
44. Ebersole BJ, Visiers I, Weinstein H, Sealfon SC: Molecular basis of partial agonism: Orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. Mol Pharmacol 2003;63:36-43.